BridgeBio Pharma, Inc.: 10-K filed 2022-02-25

Name: BridgeBio Pharma, Inc.: 10-K filed 2022-02-25
Creator: BridgeBio Pharma, Inc.

What BridgeBio Pharma, Inc. reported in its annual report filed 2022-02-25 (fiscal FY 2021): 42 published measures, 103 facts as tagged in accession 0000950170-22-002030.

This filing

Form: 10-K (annual report)
Filed: 2022-02-25
Fiscal period: fiscal FY 2021
Accession: 0000950170-22-002030 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BridgeBio Pharma, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2021-12-31	1,012,792,000	USD
At 2020-12-31	703,588,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2021-12-31	1,878,371,000	USD
At 2020-12-31	595,702,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2021-12-31	-870,414,000	USD
At 2020-12-31	57,906,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2021-12-31	393,772,000	USD
At 2020-12-31	356,082,000	USD
At 2019-12-31	363,773,000	USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-497,934,000	USD	365
2020-01-01 to 2020-12-31	-399,714,000	USD	366
2019-01-01 to 2019-12-31	-253,587,000	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	13,246,000	USD	365
2020-01-01 to 2020-12-31	7,518,000	USD	366
2019-01-01 to 2019-12-31	2,638,000	USD	365

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	69,716,000	USD	365
2020-01-01 to 2020-12-31	8,249,000	USD	366
2019-01-01 to 2019-12-31	40,560,000	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	736,446,000	USD	365
2020-01-01 to 2020-12-31	447,189,000	USD	366
2019-01-01 to 2019-12-31	398,792,000	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-200,826,000	USD	365
2020-01-01 to 2020-12-31	-52,993,000	USD	366
2019-01-01 to 2019-12-31	-217,253,000	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit
At 2021-12-31	-1,436,966,000	USD
At 2021-01-01	-874,427,000	USD
At 2020-12-31	-888,755,000	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2021-12-31	30,066,000	USD
At 2020-12-31	20,325,000	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	99,505,000	USD	365
2020-01-01 to 2020-12-31	58,459,000	USD	366
2019-01-01 to 2019-12-31	21,374,000	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-576,632,000	USD	365
2020-01-01 to 2020-12-31	-474,482,000	USD	366
2019-01-01 to 2019-12-31	-266,240,000	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2021-12-31	888,858,000	USD
At 2020-12-31	642,824,000	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	46,778,000	USD	365
2020-01-01 to 2020-12-31	36,655,000	USD	366
2019-01-01 to 2019-12-31	8,765,000	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2021-12-31	135,069,000	USD
At 2020-12-31	95,648,000	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2021-12-31	11,884,000	USD
At 2020-12-31	8,945,000	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2021-12-31	44,934,000	USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	200,000,000	USD	365
2020-01-01 to 2020-12-31	75,000,000	USD	366

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	192,210,000	USD	365
2020-01-01 to 2020-12-31	145,684,000	USD	366
2019-01-01 to 2019-12-31	94,353,000	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	451,024,000	USD	365
2020-01-01 to 2020-12-31	337,047,000	USD	366
2019-01-01 to 2019-12-31	209,947,000	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2021-12-31	147,343,323	shares
At 2020-12-31	122,849,389	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2021-12-31	-132,000	USD
At 2020-12-31	192,000	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2021-12-31	-867,002,000	USD
At 2020-12-31	106,256,000	USD
At 2019-12-31	473,733,000	USD
At 2018-12-31	377,240,000	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2021-12-31	15,907,000	USD
At 2020-12-31	16,508,000	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2021-12-31	22,366,000	USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

Period	Value	Unit	Days
At 2020-12-31	93,879,000	USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2021-12-31	44,934,000	USD
At 2020-12-31	0	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2021-12-31	33,027,000	USD
At 2020-12-31	23,931,000	USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit
At 2021-12-31	22,069,000	USD
At 2021-01-01	8,425,000	USD
At 2020-12-31	9,520,000	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2021-12-31	32,446,000	USD
At 2020-12-31	35,731,000	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2021-12-31	8,257,000	USD
At 2020-12-31	35,578,000	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-586,454,000	USD	365
2020-01-01 to 2020-12-31	-505,488,000	USD	366
2019-01-01 to 2019-12-31	-288,585,000	USD	365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-562,863,000	USD	365
2020-01-01 to 2020-12-31	-448,786,000	USD	366
2019-01-01 to 2019-12-31	-260,333,000	USD	365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-562,539,000	USD	365
2020-01-01 to 2020-12-31	-448,724,000	USD	366
2019-01-01 to 2019-12-31	-260,587,000	USD	365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	5,843,000	USD	365
2020-01-01 to 2020-12-31	1,456,000	USD	366
2019-01-01 to 2019-12-31	859,000	USD	365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	2,600,000	USD	365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	35,823,000	USD	365
2020-01-01 to 2020-12-31	1,634,000	USD	366
2019-01-01 to 2019-12-31	-1,626,000	USD	365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-9,822,000	USD	365
2020-01-01 to 2020-12-31	-31,006,000	USD	366
2019-01-01 to 2019-12-31	-22,345,000	USD	365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	29,774,000	USD	365
2020-01-01 to 2020-12-31	15,322,000	USD	366
2019-01-01 to 2019-12-31	6,092,000	USD	365

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	6,122,000	USD	365
2020-01-01 to 2020-12-31	4,169,000	USD	366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	2,833,000	USD	365
2020-01-01 to 2020-12-31	-735,000	USD	366
2019-01-01 to 2019-12-31	-4,657,000	USD	365

Inspect the source

Entity: BridgeBio Pharma, Inc. / CIK 0001743881
Captured: 2026-09-21T17:28:42.220Z
SEC response SHA-256: 33035a520f449c0cb2294b38d131bf0a0a81b13ec488fea5d3f482b6f0389c9c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001743881.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))